VMD vs EHAB

For growth investors, Viemed Healthcare, Inc.

(VMD) is the stronger pick with 20. 5% revenue growth year-over-year, versus 2. 4% for Enhabit, Inc. (EHAB). Viemed Healthcare, Inc. (VMD) offers the better valuation at 24. 9x trailing P/E (19. 2x forward), making it the more compelling value choice. Analysts rate Viemed Healthcare, Inc. (VMD) a "Buy" — based on 1 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, Viemed Healthcare, Inc.

is actually cheaper at 19. 2x.

Over the past 5 years, Viemed Healthcare, Inc.

(VMD) delivered a total return of -3. 8%, compared to -44. 9% for Enhabit, Inc. (EHAB). Over 10 years, the gap is even starker: VMD returned +413. 5% versus EHAB's -44. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Enhabit, Inc.

(EHAB) is the lower-risk stock at 0. 44β versus Viemed Healthcare, Inc. 's 0. 95β — meaning VMD is approximately 114% more volatile than EHAB relative to the S&P 500. On balance sheet safety, Viemed Healthcare, Inc. (VMD) carries a lower debt/equity ratio of 11% versus 89% for Enhabit, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Viemed Healthcare, Inc.

(VMD) is pulling ahead at 20. 5% versus 2. 4% for Enhabit, Inc. (EHAB). On earnings-per-share growth, the picture is similar: Enhabit, Inc. grew EPS 97. 1% year-over-year, compared to 32. 1% for Viemed Healthcare, Inc.. Over a 3-year CAGR, VMD leads at 24. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Viemed Healthcare, Inc.

(VMD) is the more profitable company, earning 5. 5% net margin versus -0. 4% for Enhabit, Inc. — meaning it keeps 5. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: VMD leads at 7. 7% versus 6. 0% for EHAB. At the gross margin level — before operating expenses — VMD leads at 57. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Viemed Healthcare, Inc.

(VMD) trades at 19. 2x forward P/E versus 22. 8x for Enhabit, Inc. — 3. 7x cheaper on a one-year earnings basis.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Enhabit, Inc.

(EHAB) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 44)). Both have compounded well over 10 years (EHAB: -44. 9%, VMD: +413. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: VMD is a small-cap high-growth stock; EHAB is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.